RT Journal Article
T1 Mediterranean Diet Decreases the Initiation of Use of Vitamin K Epoxide Reductase Inhibitors and Their Associated Cardiovascular Risk: A Randomized Controlled Trial.
A1 Castro-Barquero, Sara
A1 Ribó-Coll, Margarita
A1 Lassale, Camille
A1 Tresserra-Rimbau, Anna
A1 Castañer, Olga
A1 Pintó, Xavier
A1 Martínez-González, Miguel Ángel
A1 Sorlí, José V
A1 Salas-Salvadó, Jordi
A1 Lapetra, José
A1 Gómez-Gracia, Enrique
A1 Alonso-Gómez, Ángel M
A1 Fiol, Miquel
A1 Serra-Majem, Lluis
A1 Sacanella, Emilio
A1 Basterra-Gortari, Francisco Javier
A1 Portolés, Olga
A1 Babio, Nancy
A1 Cofán, Montserrat
A1 Ros, Emilio
A1 Estruch, Ramón
A1 Hernáez, Álvaro
K1 4-hydroxycoumarins
K1 Mediterranean Diet
K1 platelet aggregation inhibitors
K1 prevention
K1 randomized controlled trials
AB Our aim is to assess whether following a Mediterranean Diet (MedDiet) decreases the risk of initiating antithrombotic therapies and the cardiovascular risk associated with its use in older individuals at high cardiovascular risk. We evaluate whether participants of the PREvención con DIeta MEDiterránea (PREDIMED) study allocated to a MedDiet enriched in extra-virgin olive oil or nuts (versus a low-fat control intervention) disclose differences in the risk of initiation of: (1) vitamin K epoxide reductase inhibitors (acenocumarol/warfarin; n = 6772); (2) acetylsalicylic acid as antiplatelet agent (n = 5662); and (3) other antiplatelet drugs (cilostazol/clopidogrel/dipyridamole/ditazol/ticlopidine/triflusal; n = 6768). We also assess whether MedDiet modifies the association between the antithrombotic drug baseline use and incident cardiovascular events. The MedDiet intervention enriched with extra-virgin olive oil decreased the risk of initiating the use of vitamin K epoxide reductase inhibitors relative to control diet (HR: 0.68 [0.46-0.998]). Their use was also more strongly associated with an increased risk of cardiovascular disease in participants not allocated to MedDiet interventions (HRcontrol diet: 4.22 [1.92-9.30], HRMedDiets: 1.71 [0.83-3.52], p-interaction = 0.052). In conclusion, in an older population at high cardiovascular risk, following a MedDiet decreases the initiation of antithrombotic therapies and the risk of suffering major cardiovascular events among users of vitamin K epoxide reductase inhibitors.
YR 2020
FD 2020-12-19
LK http://hdl.handle.net/10668/16835
UL http://hdl.handle.net/10668/16835
LA en
DS RISalud
RD Apr 17, 2025